See more : Epigral Limited (EPIGRAL.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Agree Realty Corporation (ADC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Agree Realty Corporation, a leading company in the REIT – Retail industry within the Real Estate sector.
You may be interested
- The Cross-Harbour (Holdings) Limited (0032.HK) Income Statement Analysis – Financial Results
- Gayatri Sugars Limited (GAYATRI.BO) Income Statement Analysis – Financial Results
- Dollarama Inc. (DOL.TO) Income Statement Analysis – Financial Results
- Indie Ranch Media, Inc. (INDR) Income Statement Analysis – Financial Results
- Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (PAC) Income Statement Analysis – Financial Results
Agree Realty Corporation (ADC)
About Agree Realty Corporation
Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 537.50M | 463.15M | 363.61M | 248.57M | 187.48M | 148.20M | 116.56M | 91.53M | 69.97M | 53.56M | 43.52M | 35.79M | 36.32M | 36.11M | 37.26M | 35.65M | 34.47M | 32.91M | 31.58M | 29.93M | 27.47M | 25.82M | 24.68M | 23.73M | 21.93M | 19.67M | 18.23M | 16.29M | 13.80M | 9.50M |
| Cost of Revenue | 239.67M | 85.62M | 65.34M | 31.75M | 23.51M | 17.01M | 12.47M | 8.60M | 6.38M | 4.92M | 3.66M | 3.58M | 4.91M | 3.85M | 2.43M | 64.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 297.83M | 377.53M | 298.26M | 216.82M | 163.97M | 131.18M | 104.09M | 82.93M | 63.59M | 48.64M | 39.86M | 32.21M | 31.41M | 32.26M | 34.83M | 35.59M | 34.47M | 32.91M | 31.58M | 29.93M | 27.47M | 25.82M | 24.68M | 23.73M | 21.93M | 19.67M | 18.23M | 16.29M | 13.80M | 9.50M |
| Gross Profit Ratio | 55.41% | 81.51% | 82.03% | 87.23% | 87.46% | 88.52% | 89.30% | 90.61% | 90.88% | 90.82% | 91.60% | 90.00% | 86.48% | 89.34% | 93.49% | 99.82% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 0.00 | 0.37 | 0.37 | 0.37 | 0.43 | 0.43 | 0.50 | 0.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 34.79M | 30.12M | 25.46M | 20.79M | 15.57M | 12.17M | 9.95M | 8.02M | 6.99M | 6.63M | 5.95M | 5.68M | 5.66M | 5.00M | 4.56M | 6.94M | 4.46M | 4.02M | 4.19M | 2.85M | 2.28M | 2.01M | 1.81M | 1.56M | 1.42M | 1.17M | 1.11M | 1.10M | 1.00M | 700.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 88.00 | -384.00 | 859.00K | -2.58M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 34.79M | 30.12M | 25.46M | 20.79M | 15.57M | 12.17M | 9.95M | 8.02M | 6.99M | 6.63M | 5.95M | 5.68M | 5.66M | 5.00M | 5.42M | 4.36M | 4.46M | 4.02M | 4.19M | 2.85M | 2.28M | 2.01M | 1.81M | 1.56M | 1.42M | 1.17M | 1.11M | 1.10M | 1.00M | 700.00K |
| Other Expenses | 0.00 | 133.57M | 95.73M | 66.76M | 45.70M | 4.00K | 347.00K | 23.41M | 16.49M | 11.10M | 8.49M | 6.47M | 6.50M | 5.69M | 7.65M | 7.25M | 9.33M | 9.07M | 9.19M | 8.96M | 7.58M | 8.19M | 7.99M | 7.46M | 6.95M | 6.12M | 5.57M | 5.11M | -5.60M | -4.20M |
| Operating Expenses | 216.39M | 163.69M | 121.19M | 87.55M | 61.27M | 55.86M | 41.70M | 31.42M | 23.47M | 17.73M | 14.44M | 12.15M | 12.16M | 10.69M | 14.63M | 19.37M | 13.79M | 13.09M | 13.38M | 11.81M | 9.86M | 10.20M | 9.79M | 9.02M | 8.37M | 7.29M | 6.67M | 6.21M | -4.60M | -3.50M |
| Cost & Expenses | 283.11M | 249.31M | 186.53M | 119.30M | 84.78M | 72.87M | 54.17M | 40.02M | 29.85M | 22.65M | 18.10M | 15.73M | 17.07M | 14.54M | 14.63M | 19.37M | 13.79M | 13.09M | 13.38M | 11.81M | 9.86M | 10.20M | 9.79M | 9.02M | 8.37M | 7.29M | 6.67M | 6.21M | -4.60M | -3.50M |
| Interest Income | 0.00 | 63.44M | 50.38M | 40.10M | 33.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 770.18K | 1.25M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 81.12M | 63.44M | 66.35M | 44.66M | 32.98M | 0.00 | 0.00 | 0.00 | 0.00 | 8.59M | 6.48M | 5.13M | 4.73M | 4.71M | 4.64M | 5.18M | 4.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 209.37M | 212.74M | 162.25M | 123.44M | 86.39M | 64.12M | 54.17M | 40.02M | 16.49M | 11.10M | 8.49M | 6.47M | 6.50M | 5.69M | 5.71M | 5.39M | 5.20M | 4.99M | 207.04K | 4.62M | 4.82M | 4.22M | 4.22M | 4.06M | 3.80M | 3.51M | 3.19M | 3.03M | 2.60M | 2.00M |
| EBITDA | 463.95M | 386.24M | 295.67M | 192.16M | 161.45M | 118.63M | 94.14M | 74.92M | 56.60M | 42.01M | 34.05M | 26.19M | 19.73M | 14.85M | 28.34M | 21.67M | 25.88M | 24.81M | 23.15M | 17.57M | 19.81M | 19.17M | 17.97M | 18.24M | 17.29M | 15.89M | 14.75M | 13.11M | 21.00M | 15.00M |
| EBITDA Ratio | 86.32% | 74.08% | 75.47% | 77.31% | 72.92% | 74.33% | 68.59% | 71.33% | 63.81% | 78.44% | 77.92% | 74.12% | 74.44% | 96.81% | 76.05% | 60.77% | 72.05% | 75.39% | 72.28% | 75.26% | 87.07% | 74.23% | 72.83% | 76.87% | 78.84% | 80.75% | 80.91% | 76.46% | 152.17% | 157.89% |
| Operating Income | 254.39M | 218.09M | 190.27M | 125.13M | 101.09M | 73.00M | 62.39M | 51.51M | 40.11M | 27.89M | 25.42M | 20.06M | 15.60M | 13.87M | 22.63M | 16.28M | 20.68M | 19.82M | 18.21M | 18.12M | 16.65M | 15.62M | 15.10M | 14.71M | 13.56M | 12.38M | 11.56M | 10.08M | 18.40M | 13.00M |
| Operating Income Ratio | 47.33% | 47.09% | 52.33% | 50.34% | 53.92% | 49.26% | 53.53% | 56.28% | 57.33% | 52.07% | 58.41% | 56.05% | 42.94% | 38.42% | 60.73% | 45.67% | 59.99% | 60.23% | 57.65% | 60.54% | 60.61% | 60.50% | 61.20% | 61.98% | 61.83% | 62.93% | 63.40% | 61.88% | 133.33% | 136.84% |
| Total Other Income/Expenses | -80.93M | -62.19M | -64.99M | -40.07M | -33.09M | -13.69M | -3.37M | -5.71M | -351.00K | -9.12M | -6.47M | -5.13M | 506.14K | -4.71M | 0.00 | -14.46M | 1.04M | -4.62M | 12.79K | -4.29M | 176.08K | 673.58K | 1.13M | 522.34K | 68.61K | 0.00 | 0.00 | 653.07K | 0.00 | 0.00 |
| Income Before Tax | 173.46M | 155.90M | 125.28M | 93.06M | 81.30M | 59.31M | 58.79M | 45.80M | 39.76M | 18.78M | 18.95M | 14.92M | 9.55M | 15.07M | 15.48M | 15.48M | 21.72M | 0.00 | 18.22M | 18.34M | 15.17M | 16.30M | 16.23M | 15.23M | 13.63M | 0.00 | 0.00 | 10.73M | 0.00 | 0.00 |
| Income Before Tax Ratio | 32.27% | 33.66% | 34.45% | 37.44% | 43.37% | 40.02% | 50.44% | 50.04% | 56.83% | 35.05% | 43.54% | 41.70% | 26.30% | 41.72% | 41.55% | 43.42% | 63.02% | 0.00% | 57.69% | 61.27% | 55.21% | 63.11% | 65.78% | 64.18% | 62.14% | 0.00% | 0.00% | 65.89% | 0.00% | 0.00% |
| Income Tax Expense | 2.91M | 2.86M | 2.40M | 1.09M | 538.00K | 516.00K | 4.62M | 6.39M | 1.10M | 8.87M | -728.73K | -3.13M | 9.70M | 6.51M | -9.83M | -13.20M | 5.20M | 5.84M | 6.58M | 5.00M | 7.14M | 6.85M | 6.82M | 7.61M | 6.75M | 6.29M | 6.34M | 6.35M | 15.20M | 12.70M |
| Net Income | 169.96M | 152.44M | 122.27M | 91.38M | 80.08M | 58.17M | 58.11M | 45.12M | 39.02M | 18.49M | 19.68M | 18.05M | 9.55M | 15.07M | 17.99M | 15.02M | 15.48M | 13.97M | 16.05M | 13.12M | 10.47M | 8.77M | 8.07M | 7.10M | 6.81M | 6.09M | 5.22M | 3.73M | 3.20M | 300.00K |
| Net Income Ratio | 31.62% | 32.91% | 33.63% | 36.76% | 42.71% | 39.25% | 49.86% | 49.29% | 55.77% | 34.52% | 45.21% | 50.43% | 26.30% | 41.72% | 48.29% | 42.12% | 44.92% | 42.46% | 50.82% | 43.85% | 38.12% | 33.97% | 32.68% | 29.91% | 31.04% | 30.94% | 28.63% | 22.92% | 23.19% | 3.16% |
| EPS | 1.70 | 1.84 | 1.79 | 1.76 | 1.96 | 1.81 | 2.09 | 1.97 | 2.17 | 1.24 | 1.51 | 1.63 | 0.99 | 1.54 | 2.20 | 1.91 | 2.02 | 1.84 | 2.15 | 2.03 | 1.63 | 1.99 | 1.81 | 1.61 | 1.56 | 1.40 | 1.41 | 1.41 | 1.23 | 0.08 |
| EPS Diluted | 1.70 | 1.83 | 1.78 | 1.74 | 1.93 | 1.80 | 2.08 | 1.97 | 2.16 | 1.24 | 1.50 | 1.62 | 0.99 | 1.54 | 2.14 | 1.91 | 2.01 | 1.83 | 2.14 | 2.03 | 1.63 | 1.97 | 1.81 | 1.61 | 1.56 | 1.40 | 1.41 | 1.41 | 1.23 | 0.08 |
| Weighted Avg Shares Out | 95.19M | 78.66M | 66.80M | 51.84M | 40.58M | 32.07M | 27.63M | 22.87M | 18.00M | 14.88M | 13.07M | 11.07M | 9.64M | 9.76M | 7.90M | 7.68M | 7.65M | 7.59M | 7.46M | 6.46M | 4.88M | 4.45M | 4.42M | 4.41M | 4.36M | 4.36M | 3.69M | 2.65M | 2.60M | 3.21M |
| Weighted Avg Shares Out (Dil) | 95.44M | 79.16M | 67.14M | 52.40M | 41.22M | 32.40M | 27.70M | 22.96M | 18.07M | 14.97M | 13.16M | 11.14M | 9.68M | 9.76M | 8.42M | 8.38M | 7.72M | 7.64M | 7.50M | 6.46M | 5.26M | 4.45M | 4.42M | 4.41M | 4.36M | 4.36M | 3.69M | 2.65M | 2.60M | 3.21M |
Agree Realty: No Longer Undervalued, Still A Buy
Agree Realty achieves industry-leading growth at a low cost of capital, making it a fundamentally strong business and a long-term buy. REITs are expected to perform well given the lower interest rate outlook. The shares have caught up to value...
Earn A Potential 7% Monthly Income By Owning These REITs
REITs still offer high yields, in excess of 7% in some cases. Some of these high yielders also pay monthly. I highlight two of my favorite to buy today.
More Good News Ahead For REITs
REITs have rebounded due to recent Fed rate cuts, despite previous struggles with rising interest rates and the pandemic's impact on commercial real estate. I believe further upside is in store for REITs. I share why, as well as the...
Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors
MARSEILLE, France--(BUSINESS WIRE)-- #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the U.S Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to initiate a Phase 1...
Buffett-Style Investing: Finding Value In REITs
Warren Buffett invests in companies that enjoy strong moats. A moat is a major competitive advantage. This can be applied to REITs. Here is how.
2 REITs That I Have Bought With An Intent To Hold Forever
Many investors focus on selecting robust businesses with stable cash flows, reinvesting dividends to benefit from compounding, and avoiding the need for frequent trading. In the equity REIT segment, there are some possibilities to find specific names that match these...
Two Dividend-Yielding REITs With Solid Upside Potential
REITs are attractive for income investors due to their high dividend payouts, and office REITs, in particular, offer solid long-term upside as office activity could see an increase in 2025/2026. Kilroy Realty Corp. has underperformed its peers but offers a...
Dividends Are Real Money: 3 Dividend-Paying REITs To Consider
Dividends are crucial indicators of a company's financial health, providing real returns and reflecting profitability, as emphasized by Kelley Wright in "Dividends Still Don't Lie". EastGroup Properties, a premium industrial REIT, has a strong dividend growth track record and a...
Agree Realty: Still Reasonably Valued For Its Rich Growth/Dividend Thesis - Initiate Buy
Agree Realty: Still Reasonably Valued For Its Rich Growth/Dividend Thesis - Initiate Buy
Daiichi Sankyo: Showing No Signs Of Slowing Down ADC Dominance
Daiichi Sankyo's ADCs, particularly trastuzumab deruxtecan (Enhertu) and datopotamab deruxtecan, are showing promising results in treating various cancers, including HER2-mutated NSCLC and HER2-positive breast cancer. Enhertu has multiple approvals, including tissue-agnostic for high HER2 expression, while datopotamab deruxtecan shows promise...
Source: https://incomestatements.info
Category: Stock Reports